These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

737 related items for PubMed ID: 19047139

  • 1. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
    Konig H, Copland M, Chu S, Jove R, Holyoake TL, Bhatia R.
    Cancer Res; 2008 Dec 01; 68(23):9624-33. PubMed ID: 19047139
    [Abstract] [Full Text] [Related]

  • 2. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
    Reddiconto G, Toto C, Palamà I, De Leo S, de Luca E, De Matteis S, Dini L, Passerini CG, Di Renzo N, Maffia M, Coluccia AM.
    Blood; 2012 Mar 08; 119(10):2335-45. PubMed ID: 22262776
    [Abstract] [Full Text] [Related]

  • 3. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K.
    Clin Cancer Res; 2006 Oct 01; 12(19):5869-78. PubMed ID: 17020995
    [Abstract] [Full Text] [Related]

  • 4. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
    Nam S, Williams A, Vultur A, List A, Bhalla K, Smith D, Lee FY, Jove R.
    Mol Cancer Ther; 2007 Apr 01; 6(4):1400-5. PubMed ID: 17431118
    [Abstract] [Full Text] [Related]

  • 5. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606.
    Konig H, Holyoake TL, Bhatia R.
    Blood; 2008 Feb 15; 111(4):2329-38. PubMed ID: 18056843
    [Abstract] [Full Text] [Related]

  • 6. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
    Chu S, Holtz M, Gupta M, Bhatia R.
    Blood; 2004 Apr 15; 103(8):3167-74. PubMed ID: 15070699
    [Abstract] [Full Text] [Related]

  • 7. Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors.
    Hiwase DK, White DL, Powell JA, Saunders VA, Zrim SA, Frede AK, Guthridge MA, Lopez AF, D'Andrea RJ, To LB, Melo JV, Kumar S, Hughes TP.
    Leukemia; 2010 Apr 15; 24(4):771-8. PubMed ID: 20130598
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
    Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE.
    Oncogene; 2002 Nov 21; 21(53):8075-88. PubMed ID: 12444544
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.
    Lin H, Chen M, Rothe K, Lorenzi MV, Woolfson A, Jiang X.
    Oncotarget; 2014 Sep 30; 5(18):8637-50. PubMed ID: 25226617
    [Abstract] [Full Text] [Related]

  • 12. MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.
    Nguyen TK, Rahmani M, Harada H, Dent P, Grant S.
    Blood; 2007 May 01; 109(9):4006-15. PubMed ID: 17218385
    [Abstract] [Full Text] [Related]

  • 13. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.
    Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK, Nicolini FE, Müller-Tidow C, Bhatia R, Brunton VG, Koschmieder S, Holyoake TL.
    Blood; 2012 Feb 09; 119(6):1501-10. PubMed ID: 22184410
    [Abstract] [Full Text] [Related]

  • 14. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.
    Wisniewski D, Lambek CL, Liu C, Strife A, Veach DR, Nagar B, Young MA, Schindler T, Bornmann WG, Bertino JR, Kuriyan J, Clarkson B.
    Cancer Res; 2002 Aug 01; 62(15):4244-55. PubMed ID: 12154026
    [Abstract] [Full Text] [Related]

  • 15. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein.
    Carlo-Stella C, Dotti G, Mangoni L, Regazzi E, Garau D, Bonati A, Almici C, Sammarelli G, Savoldo B, Rizzo MT, Rizzoli V.
    Blood; 1996 Oct 15; 88(8):3091-100. PubMed ID: 8874208
    [Abstract] [Full Text] [Related]

  • 16. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
    Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S.
    Proc Natl Acad Sci U S A; 2006 Nov 07; 103(45):16870-5. PubMed ID: 17077147
    [Abstract] [Full Text] [Related]

  • 17. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
    Guo Y, Shan Q, Gong Y, Lin J, Yang X, Zhou R.
    Cancer Biol Ther; 2012 Nov 07; 13(13):1244-54. PubMed ID: 22895079
    [Abstract] [Full Text] [Related]

  • 18. Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib.
    Dumka D, Puri P, Carayol N, Lumby C, Balachandran H, Schuster K, Verma AK, Terada LS, Platanias LC, Parmar S.
    Leuk Lymphoma; 2009 Dec 07; 50(12):2017-29. PubMed ID: 19672773
    [Abstract] [Full Text] [Related]

  • 19. Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.
    Härtel N, Klag T, Hanfstein B, Mueller MC, Schenk T, Erben P, Hochhaus A, La Rosée P.
    J Cancer Res Clin Oncol; 2012 Feb 07; 138(2):203-12. PubMed ID: 22089930
    [Abstract] [Full Text] [Related]

  • 20. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
    Golas JM, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J, Frost P, Ye F, Boschelli DH, Boschelli F.
    Cancer Res; 2003 Jan 15; 63(2):375-81. PubMed ID: 12543790
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.